drugset / Trial / NCT01624532
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
Phase 2
Completed
240 enrolled
Green Cross Corporation
Korean Center for Disease Control and Prevention · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects.
Timeline
- Start
- 2021-07-14
- Primary completion
- 2022-08-02
- Completion
- 2022-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC1109 | Vaccine | 0.1 ml | Intramuscular |
| Subject | GC1109 | Vaccine | 0.3 ml | Intramuscular |
| Subject | GC1109 | Vaccine | 0.5 ml | Intramuscular |
| Subject | GC1109 | Vaccine | 1 ml | Intramuscular |